A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases-Reference-Cited by-同舟云学术

A Phase 1, Open-Label Study of the Biodistribution, Pharmacokinetics, and Dosimetry of 223Ra-Dichloride in Patients with Hormone-Refractory Prostate Cancer and Skeletal Metastases

Published:2015-07-16 Issue:9 Volume:56 Page:1304-1309
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Chittenden Sarah J.,Hindorf Cecilia,Parker Christopher C.,Lewington Valerie J.,Pratt Brenda E.,Johnson Bernadette,Flux Glenn D.

Publisher

Society of Nuclear Medicine

Subject

Radiology Nuclear Medicine and imaging

Reference29 articles.

1. Radiopharmaceutical and Chemotherapy Combinations in Metastatic Castrate-Resistant Prostate Cancer: A New Beginning?

2. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

3. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

4. Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments

Cited by 97 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physics for molecular radiotherapy – The battle between science and simplicity;Physica Medica;2024-08

2. Qualitative and quantitative imaging of alpha‐emitting radiopharmaceuticals;iRADIOLOGY;2024-06-25

3. ISIT-QA: In Silico Imaging Trial to Evaluate a Low-Count Quantitative SPECT Method Across Multiple Scanner–Collimator Configurations for²²³Ra-Based Radiopharmaceutical Therapies;Journal of Nuclear Medicine;2024-04-04

4. Dosimetry for Radiopharmaceutical Therapy;2024-04

5. Micellar solution of [223Ra]RaCl2: Reaching renal excretion, potent efficacy in osteoblastic osteosarcoma in PDX model, biochemistry alterations and pharmacokinetics;International Journal of Pharmaceutics;2024-03